| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
29,740,000 |
| Market
Cap: |
69.00(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.28 - $21.53 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines for patients with rare infectious diseases. Co.'s initial product candidate, epetraborole, an antibiotic under development as a once-daily, oral treatment for patients with chronic non-tuberculous mycobacterial lung disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,787,778 |
1,894,632 |
| Total Buy Value |
$0 |
$0 |
$16,053,772 |
$16,898,592 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
9 |
| Total Shares Sold |
0 |
321,491 |
565,631 |
657,255 |
| Total Sell Value |
$0 |
$6,268,666 |
$10,233,675 |
$11,689,612 |
| Total People Sold |
0 |
6 |
6 |
6 |
| Total Sell Transactions |
0 |
12 |
36 |
50 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Krause Kevin Michael |
Chief Strategy Officer |
• • – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
31,914 |
|
- |
|
| Chanda Sanjay |
Chief Development Officer |
• • – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
28,235 |
|
- |
|
| Day Lucy |
Chief Financial Officer |
• • – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
30,627 |
|
- |
|
| Eizen Joshua M |
Chief Legal Officer |
• • – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
32,447 |
|
- |
|
| Easom Eric |
Chief Executive Officer |
• • – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
99,000 |
101,130 |
|
- |
|
| Eckburg Paul |
Chief Medical Officer |
• • – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
51,416 |
|
- |
|
| Zakrzewski Joseph S |
|
– • – |
2024-01-18 |
4 |
S |
$19.11 |
$1,911,410 |
I/I |
(100,000) |
405,880 |
|
89% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2024-01-16 |
4 |
S |
$19.65 |
$312,573 |
I/I |
(15,907) |
377,542 |
|
89% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2024-01-16 |
4 |
S |
$19.65 |
$1,652,427 |
D/D |
(84,093) |
1,995,958 |
|
89% |
|
| Aziz Kabeer |
|
– • – |
2024-01-16 |
4 |
S |
$19.65 |
$1,965,000 |
I/I |
(100,000) |
377,542 |
|
89% |
|
| Readnour Robin Shane |
Director |
– • – |
2024-01-12 |
4 |
AS |
$21.91 |
$31,229 |
I/I |
(1,425) |
485,073 |
|
-89% |
|
| Readnour Robin Shane |
Director |
– • – |
2024-01-10 |
4 |
AS |
$21.92 |
$80,443 |
I/I |
(3,669) |
485,792 |
|
-89% |
|
| Krause Kevin Michael |
Chief Strategy Officer |
• • – |
2024-01-09 |
4 |
AS |
$20.14 |
$149,367 |
D/D |
(7,417) |
1,914 |
|
-89% |
|
| Krause Kevin Michael |
Chief Strategy Officer |
• • – |
2024-01-09 |
4 |
OE |
$0.42 |
$34,015 |
D/D |
7,417 |
9,331 |
|
- |
|
| Easom Eric |
Chief Executive Officer |
• • – |
2024-01-02 |
4 |
AS |
$20.09 |
$55,802 |
D/D |
(2,777) |
2,130 |
|
-88% |
|
| Krause Kevin Michael |
Chief Strategy Officer |
• • – |
2024-01-02 |
4 |
AS |
$20.12 |
$51,967 |
D/D |
(2,583) |
1,914 |
|
-88% |
|
| Krause Kevin Michael |
Chief Strategy Officer |
• • – |
2024-01-02 |
4 |
OE |
$0.42 |
$1,085 |
D/D |
2,583 |
4,497 |
|
- |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-11-14 |
4 |
AS |
$16.15 |
$4,650 |
I/I |
(288) |
393,449 |
|
-80% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-11-14 |
4 |
AS |
$16.15 |
$24,574 |
D/D |
(1,522) |
2,080,051 |
|
-80% |
|
| Aziz Kabeer |
|
– • • |
2023-11-14 |
4 |
AS |
$16.15 |
$29,224 |
I/I |
(1,810) |
393,449 |
|
-80% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-10-02 |
4 |
AS |
$16.07 |
$14,495 |
I/I |
(902) |
393,737 |
|
29% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-10-02 |
4 |
AS |
$16.07 |
$76,654 |
D/D |
(4,770) |
2,081,573 |
|
29% |
|
| Aziz Kabeer |
|
– • • |
2023-10-02 |
4 |
AS |
$16.07 |
$91,149 |
I/I |
(5,672) |
393,737 |
|
29% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-09-29 |
4 |
AS |
$16.28 |
$256,638 |
I/I |
(15,764) |
394,639 |
|
24% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-09-29 |
4 |
AS |
$16.28 |
$1,356,726 |
D/D |
(83,337) |
2,086,343 |
|
24% |
|
88 Records found
|
|
Page 1 of 4 |
|
|
0.04 (1.75%) 
